To the Editor We read with great interest the study by Tsakiridis and colleagues1 assessing the efficacy and safety of the addition of metformin to chemoradiotherapy in unresected locally advanced non–small cell lung cancer. Conclusions were drawn in this multicenter randomized clinical trial that the addition of metformin was associated with poorer outcomes and more adverse effects than chemoradiotherapy alone.
Liang J, Zhan C, Wang Q. Metformin—A Thought-provoking Addition to Anticancer Therapies. JAMA Oncol. 2022;8(2):303. doi:10.1001/jamaoncol.2021.6726
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.